Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis

[Guest guest]

AIDS

January 2, 2008, 22:1

Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in

patients with HIV/hepatitis B virus co-infection.

Research Letters

AIDS. 22(1):152-154, January 2, 2008.

Nuesch, Reto a,b; Ananworanich, Jintanat a; Srasuebkul, Preeyaporn c;

Chetchotisakd, Ploenchan d; Prasithsirikul, Wisit e; Klinbuayam, Wirat f;

Mahanontharit, Apicha a; Jupimai, Thidarat a; Ruxrungtham, Kiat a; Hirschel,

Bernard g

Abstract:

Thai patients enrolled in STACCATO with HIV/hepatitis B virus (HBV) co-infection

and tenofovir/emtricitabine-based antiretroviral therapy (ART) were randomly

assigned to continuous treatment or CD4 cell count-guided interruptions. HBV

replication was suppressed below detection in 15/16 patients. Structured

treatment interruption increased transaminases and HBV viraemia in five of six

patients; one flare was severe. Conversion to anti-hepatitis Be occurred with

continuous treatment only. Tenofovir/emtricitabine-containing ART is highly

effective in controlling chronic HIV/HBV co-infection but treatment should not

be interrupted.

http://www.aidsonline.com/pt/re/aids/abstract.00002030-200801020-00020.htm;jsess\

ionid=H2bbJ5hCVqLk1VM3TvJn8BhL1YHz38xd1Fn5y4bg1PYXZlDmGZNc!1390229169!181195629!\

8091!-1

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008